|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, these EBV-bearing cells in lymphoma tissues were shown to be of B-cell lineage, by the combinated analysis of immunostaining with CD20 and ISH with EBER1.
|
7661694 |
1995 |
|
Adult Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This is the first identified case of loss of CD20 expression in a lymphoma that has relapsed after rituximab therapy, although several other cases have since been identified.
|
10100713 |
1999 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MHC class I-negative lymphoma cells (Daudi) were labelled with a biotinylated mAb specific for a cell surface protein (anti-CD20) then linked to soluble biotinylated HLA-A2/gag complexes using an avidin bridge.
|
10737389 |
2000 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD20 Abs induce clinical responses in lymphoma patients, but there are considerable differences between individual patients.
|
11067958 |
2000 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The lymphoma cell was positive for CD20 and T cell lineage markers such as cytoplasmic CD3, CD4, and CD5 and had a monoclonal rearrangement of the T cell receptor (TCR) gamma chain gene.
|
11475154 |
2001 |
|
Adult Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Additional immunostaining, which demonstrated positivity for CD20 and kappa light chain, as well as detection of the monoclonal rearrangement of the immunoglobulin heavy chain gene, helped to establish the diagnosis of lymphoma and to rule out an initially favored diagnosis of poorly differentiated carcinoma.
|
11473470 |
2001 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrate that 10 mg/mL rituximab saturated 80-95% of CD20 molecules per cell in all tested lymphoma samples.
|
11801463 |
2002 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have set up a new in vivo model in nonimmunodeficient mice by stable transduction of the human CD20 cDNA in the murine lymphoma line EL4.Animals injected i.v. with the EL4-CD20(+) lymphoma cells died within 30 days with evident liver, spleen, and bone marrow involvement, confirmed by immunohistochemistry and PCR analysis.
|
12874252 |
2003 |
|
Adult Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A patient with fibrosing alveolitis developed a diffuse large B-cell (DLBC) lymphoma that expressed CD20 and CD30.
|
15257558 |
2004 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We and others have previously reported that immunoglobulin G Fc receptor (FcgammaR) polymorphisms predict the clinical response of lymphoma patients to passive anti-CD20 antibody infusions.
|
15483014 |
2004 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We describe 2 elderly patients with Human herpesvirus 8 (HHV-8)/Kaposi sarcoma herpes virus negative malignant effusion lymphoma showing pan-B-cell immunophenotyping markers and successfully treated with a chimeric anti-CD20 IgG1 monoclonal antibody, rituximab.
|
15621832 |
2005 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 14 patients with high-risk CD20+ lymphoma underwent an autologous peripheral blood stem cell transplantation (APBSCT).
|
16923109 |
2006 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A pilot trial of rituximab and LAK cells in patients with rituximab-refractory CD20+ lymphoma was conducted to evaluate this approach.
|
17438098 |
2007 |
|
Adult Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The therapeutic mAb rituximab induced the expression of the CCL3 and CCL4 chemokines in the human lymphoma line BJAB following binding to the CD20 Ag.
|
17475893 |
2007 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have established a CD20- lymphoma cell line, RRBL1, from a diffuse large B-cell lymphoma with CD20- transformation from CD20+ follicular lymphoma after treatment with rituximab.
|
17675267 |
2007 |
|
Adult Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Importantly, in contrast to parental NK-92, CD20-specific NK cells efficiently lysed CD20 expressing but otherwise NK-resistant established and primary lymphoma and leukemia cells, demonstrating that this strategy can overcome NK-cell resistance and might be suitable for the development of effective cell-based therapeutics for the treatment of B-cell malignancies.
|
17717662 |
2008 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The recombinant antibodies were detected in the milk of transgenic mice with the highest expression level up to 17 microg/mul and could specifically bind the CD20 surface antigens on human B-lymphoma cells.
|
18183493 |
2008 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The anti-CD20 monoclonal antibody rituximab has been less successful in treating chronic lymphocytic leukemia (CLL) than lymphoma, possibly due to the lower density of CD20 on B lymphocytes from CLL patients than on those from lymphoma patients.
|
18794139 |
2008 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment of patients with relapsed or refractory low grade follicular B-NHL lymphoma with rituximab (chimeric anti-CD20 mAb) has resulted in approximately 50% response rate.
|
19885551 |
2009 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rituximab (RTX), for which CD20 molecule is the target, proved to be less efficient in CLL than in lymphoma.
|
19758221 |
2009 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combination treatment with 4-1BBL/anti-CD20 fusion protein and anti-CD3/anti-CD20 diabody led to significantly increased T-cell cytotoxicity to human B-lymphoma cells in vitro and drastically more potent tumor inhibitory activity in vivo in xenografted B-cell lymphoma in severe combined immunodeficiency disease mice.
|
20463597 |
2010 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Measles virus (MV)-PNP H(blind)antiCD20 is a CD20-targeted and prodrug convertase-armed MV that temporarily controls growth of lymphoma xenografts in severe combined immunodeficiency (SCID) mice in combination with fludarabine phosphate (fludarabine).
|
20686506 |
2010 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The anti-CD20 monoclonal antibody (mAb) rituximab has been used successfully for lymphoma therapy for more than 10 years.
|
20439625 |
2010 |
|
Adult Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The study showed that lymphoma xenografts could be targeted in the presence of endogenous biotin when anti-CD20 fusion proteins containing SAv mutants (scFv(4)-SAv-S45A or scFv(4)-SAv-Y43A) were employed in combination with CA 2 and [(111)In]4b.
|
20597486 |
2010 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fusion proteins had reduced IFNalpha activity in vitro compared with native IFNalpha, but CD20 targeting permitted efficient antiproliferative and proapoptotic effects against an aggressive rituximab-insensitive human CD20(+) murine lymphoma (38C13-huCD20) and a human B-cell lymphoma (Daudi).
|
20139095 |
2010 |